MX2020003395A - Composiciones y metodos para tratar linfoma difuso de celulas b grandes. - Google Patents
Composiciones y metodos para tratar linfoma difuso de celulas b grandes.Info
- Publication number
- MX2020003395A MX2020003395A MX2020003395A MX2020003395A MX2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- cell lymphoma
- diffuse large
- treating diffuse
- Prior art date
Links
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 title abstract 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960003008 blinatumomab Drugs 0.000 abstract 2
- 229960002621 pembrolizumab Drugs 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571870P | 2017-10-13 | 2017-10-13 | |
| PCT/US2018/055667 WO2019075366A1 (en) | 2017-10-13 | 2018-10-12 | COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003395A true MX2020003395A (es) | 2020-08-03 |
Family
ID=64110107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003395A MX2020003395A (es) | 2017-10-13 | 2018-10-12 | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. |
| MX2024001888A MX2024001888A (es) | 2017-10-13 | 2020-07-13 | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001888A MX2024001888A (es) | 2017-10-13 | 2020-07-13 | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200262919A1 (enExample) |
| EP (1) | EP3694520A1 (enExample) |
| JP (2) | JP2020536923A (enExample) |
| KR (1) | KR20200068655A (enExample) |
| CN (1) | CN111212646A (enExample) |
| AU (1) | AU2018347457A1 (enExample) |
| BR (1) | BR112020007203A2 (enExample) |
| CA (1) | CA3075291A1 (enExample) |
| CL (1) | CL2020000973A1 (enExample) |
| EA (1) | EA202090565A1 (enExample) |
| IL (1) | IL273805A (enExample) |
| MX (2) | MX2020003395A (enExample) |
| SG (1) | SG11202002374RA (enExample) |
| TW (1) | TW201922283A (enExample) |
| WO (1) | WO2019075366A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| US20230146593A1 (en) * | 2020-03-12 | 2023-05-11 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor |
| KR20230084561A (ko) * | 2020-10-12 | 2023-06-13 | 그레펙스 인코포레이티드 | Sars-cov 단백질 발현 세포로 t 세포 반응을 표적화하는 항체 작제물, 이의 설계 및 용도 |
| KR20250110243A (ko) * | 2022-11-01 | 2025-07-18 | 테네오투, 인크. | 비호지킨 림프종 치료 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发（慕尼黑）股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| WO2016196173A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
| WO2017004532A1 (en) * | 2015-07-02 | 2017-01-05 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
-
2018
- 2018-10-12 KR KR1020207009219A patent/KR20200068655A/ko not_active Ceased
- 2018-10-12 US US16/648,568 patent/US20200262919A1/en not_active Abandoned
- 2018-10-12 AU AU2018347457A patent/AU2018347457A1/en not_active Abandoned
- 2018-10-12 SG SG11202002374RA patent/SG11202002374RA/en unknown
- 2018-10-12 EA EA202090565A patent/EA202090565A1/ru unknown
- 2018-10-12 WO PCT/US2018/055667 patent/WO2019075366A1/en not_active Ceased
- 2018-10-12 BR BR112020007203-6A patent/BR112020007203A2/pt unknown
- 2018-10-12 MX MX2020003395A patent/MX2020003395A/es unknown
- 2018-10-12 CN CN201880066675.2A patent/CN111212646A/zh active Pending
- 2018-10-12 JP JP2020520587A patent/JP2020536923A/ja active Pending
- 2018-10-12 EP EP18797306.0A patent/EP3694520A1/en not_active Withdrawn
- 2018-10-12 CA CA3075291A patent/CA3075291A1/en active Pending
- 2018-10-15 TW TW107136236A patent/TW201922283A/zh unknown
-
2020
- 2020-04-05 IL IL273805A patent/IL273805A/en unknown
- 2020-04-09 CL CL2020000973A patent/CL2020000973A1/es unknown
- 2020-07-13 MX MX2024001888A patent/MX2024001888A/es unknown
-
2023
- 2023-09-27 JP JP2023164647A patent/JP2024001071A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201922283A (zh) | 2019-06-16 |
| IL273805A (en) | 2020-05-31 |
| JP2020536923A (ja) | 2020-12-17 |
| WO2019075366A1 (en) | 2019-04-18 |
| EA202090565A1 (ru) | 2020-10-13 |
| CN111212646A (zh) | 2020-05-29 |
| US20200262919A1 (en) | 2020-08-20 |
| KR20200068655A (ko) | 2020-06-15 |
| MX2024001888A (es) | 2024-02-29 |
| CA3075291A1 (en) | 2019-04-18 |
| EP3694520A1 (en) | 2020-08-19 |
| JP2024001071A (ja) | 2024-01-09 |
| AU2018347457A1 (en) | 2020-04-09 |
| CL2020000973A1 (es) | 2020-12-28 |
| BR112020007203A2 (pt) | 2020-10-20 |
| SG11202002374RA (en) | 2020-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| PH12022550348A1 (en) | Materials and methods for improved single chain variable fragments | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2021006235A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
| MX2024001888A (es) | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. | |
| SA518391159B1 (ar) | مترافقات الألفة- قليلة النيوكليوتيد واستخداماتها | |
| MX2021003169A (es) | Metodos para purificar anticuerpos multiespecificos, heterodimericos. | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| EA201792443A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| TR2021016542A2 (tr) | Plazma bazlı filmler ve bunları üretme ve kullanma usulleri. | |
| GEP20247583B (en) | Methods for treating condi tions associated with masp-2 dependent complement activation | |
| SG11201906123VA (en) | Method for random access and terminal device | |
| EA201991818A1 (ru) | Лечение рака | |
| MX382996B (es) | Inhibidores de pcna | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| PH12019500070A1 (en) | Uses of indolinone compounds | |
| MX2018016196A (es) | Metodos para muestrear metabolitos gingivales. | |
| PH12020551292A1 (en) | Moscato wine replicas produced from individual components | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| JOP20190164B1 (ar) | تركيبات وطرق لعلاج داء فاربر | |
| EP4354134A3 (en) | Sorbents, devices, kits and methods useful for biological sample treatment | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| PH12021553111A1 (en) | Sake replicas produced from individual components |